

**CERTIFICATION FORM:
Free EPIPEN® (epinephrine injection, USP) Auto-Injector for
EPIPEN4SCHOOLS® Program**

The school and/or school district identified below (the "School") hereby acknowledges and agrees that the Free EPIPEN (epinephrine injection, USP) Auto-Injector for EPIPEN4SCHOOLS Program made available by Viatris™ ("Viatris") to the School is because it is a school and is conditioned upon the undersigned making this certification to Viatris.

The School represents and warrants to Viatris that:

- (i) all of the information provided in this certification is true, complete and accurate;
- (ii) the School will only receive EPIPEN (epinephrine injection, USP) 0.3mg and EPIPEN JR® (epinephrine injection, USP) 0.15mg Auto-Injectors, or authorized generic for EPIPEN (epinephrine injection, USP) 0.3mg and EPIPEN JR (epinephrine injection, USP) 0.15mg Auto-Injectors, in accordance with all applicable laws for use by the School, and the School has presented a valid prescription for the product;
- (iii) the School is an entity whose primary purpose is education for students in grades K through 12 that is licensed as an educational facility under all applicable laws;
- (iv) the School shall make best efforts to provide appropriate product training to any School personnel who may administer an EPIPEN or EPIPEN JR Auto-Injectors or authorized generic for EPIPEN or EPIPEN JR Auto-Injectors;
- (v) the person signing this certification on behalf of the School has the requisite authority to make this certification on behalf of the School identified below;
- (vi) such EPIPEN Auto-Injectors or authorized generic for EPIPEN Auto-Injectors received by the School shall be for its own use and the School shall not sell or transfer any such EPIPEN Auto-Injectors or authorized generic for EPIPEN Auto-Injectors received pursuant to the Free EPIPEN Auto-Injector for EPIPEN4SCHOOLS Program to a non-school third party, unless the prior written approval of Viatris, in its sole discretion, is obtained;
- (vii) any transfer of any quantity of EPIPEN Auto-Injectors or authorized generic for EPIPEN Auto-Injectors received pursuant to the Free EPIPEN Auto-Injector for EPIPEN4SCHOOLS Program available to schools in violation of this certification will be considered a breach of this certification allowing Viatris to prohibit the School from receiving EPIPEN Auto-Injectors or authorized generic for EPIPEN Auto-Injectors pursuant to the Free EPIPEN Auto-Injector for EPIPEN4SCHOOLS Program available to schools;
- (viii) neither the School, nor any healthcare professional associated with or providing medical services on behalf of the School, will bill any patient or any third-party payer/government program for any free EPIPEN or EPIPEN JR Auto-Injector or authorized generic for EPIPEN or EPIPEN JR Auto-Injector administered to any patient; and

Please input the number of EPIPEN 2-PAK and/or EPIPEN JR 2-PAK cartons below.

Authorized Schools are eligible to receive four EPIPEN Auto-Injectors in the form of two EPIPEN 2-PAK cartons; or two EPIPEN JR 2-PAK cartons; or one of each 2-PAK cartons. Total quantity ordered must be no more than two 2-PAK cartons.

Product/Carton Type	Quantity Ordered*	Price
EPIPEN 2-PAK Cartons		FREE
EPIPEN JR 2-PAK Cartons		FREE
Total Quantity Ordered *must be no more than two 2-PAK		FREE

**Please note there are two auto-injectors per EPIPEN 2-PAK or EPIPEN JR 2-PAK. Example: If you wish to order two EPIPEN Auto-Injectors and two EPIPEN JR Auto-Injectors, put the number "1" in the Quantity Ordered box next to EPIPEN 2-PAK and "1" in the Quantity Ordered box next to EPIPEN JR 2-PAK. If you wish to order four EPIPEN JR Auto-Injectors, put the number "2" in the Quantity Ordered box next to EPIPEN JR 2-*

PAK® and 0 (zero) in the Quantity Ordered box next to EPIPEN 2-PAK. **Please note that Schools may receive the authorized generic versions of EPIPEN and EPIPEN JR.**

† **ORDERING FOR MULTIPLE SCHOOLS:** If you are ordering for multiple Schools within a single school district, you may order up to two 2-PAK cartons per school. Please provide a list of all of the Schools for which you are ordering product if ordering for multiple Schools, including the name and address of each School. For example, if you are ordering two EPIPEN JR 2-PAK cartons for each of 10 Schools, you should enter 20 in the Quantity Ordered column next to EPIPEN JR 2-PAK cartons. Under this scenario, your total quantity ordered cannot exceed the number of Schools multiplied by 2.

If the terms and conditions provided in this certification are amended, modified or altered in any way, it will be considered null and void.

School/School District Name:	
School Address:	
City/State/Zip:	
School Phone:	
Authorized School Signatory Name:	
Authorized School Signatory Title:	
Authorized School Signatory Email:	
Signature:	Date:

Please fax the completed Certification Form and a copy of a valid EPIPEN Auto-Injector prescription to BioRidge Pharma, LLC
Attn: Kristina Paich Fax: 973-718-4328 or email scan to: info@bioridgepharma.com
Phone: 973-845-7600

Indications (the following information applies to both EPIPEN and its Authorized Generic)

EPIPEN and EPIPEN JR Auto-Injectors are indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. EPIPEN and EPIPEN JR Auto-Injectors are intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.

Important Safety Information (the following information applies to both EPIPEN and its Authorized Generic)

EPIPEN (epinephrine injection, USP) 0.3 mg and EPIPEN JR (epinephrine injection, USP) 0.15 mg Auto-Injectors are intended for immediate administration as emergency supportive therapy only and are not intended as a substitute for immediate medical or hospital care. **In conjunction with the administration of epinephrine, the patient should seek immediate medical or hospital care.** More than two sequential doses of epinephrine should only be administered under direct medical supervision.

EPIPEN and EPIPEN JR should **only** be injected into the anterolateral aspect of the thigh. **Do not inject intravenously, into buttock, or into digits, hands, or feet.** Instruct caregivers to hold the leg of young children firmly in place and limit movement prior to and during injection to minimize risk of injection-related injury.

Rare cases of serious skin and soft tissue infections have been reported following epinephrine injection. Advise patients to seek medical care if they develop symptoms of infection such as persistent redness, warmth, swelling, or tenderness at the injection site.

Epinephrine should be used with caution in patients with heart disease, and in patients who are on drugs that may sensitize the heart to arrhythmias, because it may precipitate or aggravate angina pectoris and produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.

Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions. Common adverse reactions to epinephrine include anxiety, apprehensiveness, restlessness, tremor, weakness, dizziness, sweating, palpitations, pallor, nausea and vomiting, headache, and/or respiratory difficulties.

Please see the [Full Prescribing Information](#) for EPIPEN

Please see the [Full Prescribing Information](#) for the Authorized Generic for EPIPEN

EPIPEN, EPIPEN JR, EPIPEN 2-PAK, EPIPEN JR 2-PAK, and *EPIPEN4SCHOOLS* are registered trademarks of Mylan Inc., a Viatris Company

VIATRIS is a trademark of Mylan Inc., a Viatris Company.

© 2021 Viatris Inc. All rights reserved. EPI-2021-0493